Advanced Heart Failure

Key dilated cardiomyopathy publications, presentations and abstracts of Vericel Corporation are listed in chronological order below and available for download in PDF.

Journal Articles

Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial
Amit N Patel*, Timothy D Henry*, Arshed A Quyyumi, Gary L Schaer, R David Anderson, Catalin Toma, Cara East, Ann E Remmers, James Goodrich, Akshay S Desai, David Recker, Anthony DeMaria, for The ixCELL-DCM Investigators The Lancet. Volume 387, No. 10036, p2412-2421, 11 June 2016.

The iXCELL-DCM Trial: Rationale and Design
Timothy D. Henry, Gary L. Schaer, Anthony DeMaria, David Recker, Ann E. Remmers, James Goodrich, Amit Patel. CT-1575 Cell Transplantation early e-pub; March 21, 2016.

Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy
Timothy D. Henry, Jay H Traverse, Baron L. Hammon, Cara A. East, Brian Bruckner, Ann E. Remmers, David Recker, David A. Bull, and Amit N. Patel. Circulation Research, August 20, 2014.

Safety and Efficacy of Ixmyelocel-T, An Expanded, Autologous Multi-Cellular Therapy, Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases
Kelly J Ledford, Nikki Murphy, Frank Zeigler, Ronnda L Bartel and Ross Tubo. Stem Cell Research & Therapy (2015) 6:25

Potential Beneficial Effects of Ixmyelocel-T in the Treatment of Atherosclerotic Diseases
KJ Ledford, N Murphy, F Zeigler, RL Bartel. Stem Cell Research & Therapy, November 2013.

Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
KJ Ledford, F Zeigler, RL Bartel. Stem Cell Research & Therapy, November 2013.

Safety and Efficacy of Ixmyelocel-T, An Expanded Patient-Specific Mixed Cell Product, in Dilated Cardiopyopathy (IMPACT-DCM)
Brian Bruckner, Amit N. Patel, Baron L. Hamman, Omar M. Lattouf, Nicholas G. Smedira, Ronnda L. Bartel, and Sharon Watling. International Society for Heart and Lung Transplantation, November 2011.

Tissue Repair Cells for the Treatment of Cardiovascular Diseases
K. Goltry, J. Rowley, M. Peters, E. Burchardt. Advances in Molecular Medicine, Vol. 3(1): 5-13, 2007.

Presentations & Posters

The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in Patients with Ischemic Dilated Cardiomyopathy
Timothy D. Henry, MD, FACC on behalf of Arshed A. Quyyumi, Gary L. Schaer, David R. Anderson, Catalin Toma, Cara East, David P. Recker, Ann Remmers, James Goodrich, Amit N. Patel and the ixCELL-DCM Investigators

Potential Atheroprotective Effects of Ixmyelocel-T Cellular Therapy
KJ Ledford, EN Murphy, F Zeigler, RL Bartel, International Society of Cellular Therapy 2013 Annual Meeting

Ixmyelocel-T, A Unique Mixed Cellular Therapy for the Treatment of Vascular Diseases Associated with Endothelial Dysfunction
KJ Ledford, EN Murphy, F Zeigler, RL Bartel, AHA Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, May 2013

Ixmyelocel-T Therapy Alternatively Activated Macrophages Potentially Exert Atheroprotective Effects
KJ Ledford, C Parrish, F Zeigler, RL Bartel. Keystone Symposia on the Molecular Basis of Vascular Inflammation and Atherosclerosis in Big Sky, Montana, starting Sunday, March 2012.

Safety and Efficacy of Ixmyelocel-T, A Patient-Specific Expanded Multicellular Therapy, in Dilated Cardiomyopathy
Timothy D. Henry, Jay H. Traverse, Rod Badger, Marco Costa, Patricia Mitchell, Kristen Kolsch, Ronnda L. Bartel, Sharon Watling, Amit N. Patel. Society for Cardiovascular Angiography and Interventions (SCAI), May 2012.

IMPACT-DCM 12 Month Study Update
Brian Bruckner, MD. International Society for Heart & Lung Transplantation (ISHLT), April 2012.

Aastrom Presents Results From Two Studies of Autologous Bone Marrow-Derived ixmyelocel-T at the International Society for Cellular Therapy Meeting

  1. 1) Autologous Bone Marrow-Derived Cells (Ixmyelocel-T) Contain Mesenchymal Stem Cells Expressing B7H3 and Modulate Immune Response In Vitro
    F. Zeigler, C. Parrish, J. Osborne, A. Wong, P. Kulasekaran, and R. Bartel. International Society for Cellular Therapy, May 2011.
  2. 2) Autologous Tissue Repair Cells from Bone Marrow Require MAC-1 Integrin Function for Expansion of Both Hematopoietic Cells and Mesenchymal Stem Cells
    J. Osborne, K. Ledford, C. Parrish , A. Wong, F. Zeigler, and R. Bartel. International Society for Cellular Therapy, May 2011.